IGF1 and neoplasm: Using the clinical decision support tool, Acromegaly Disease Activity Tool (ACRODAT®), which assesses five parameters: IGF-I levels, tumour status, comorbid conditions, signs/symptoms and QoL, the AcroVoice study found that these parameters were important to patients.